Keywords
Obesity
Pharmacological treatment
How to Cite
Abstract
Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by early-onset obesity, muscle hypotonia, hypogonadism, and behavioral disorders, and is a relevant challenge for Brazilian public health. This study aimed to evaluate the pharmacological options available for the management of obesity and behavioral disorders associated with PWS in the context of the Unified Health System (SUS). The methodology consisted of an integrative review of the literature, including studies published in the last five years in databases such as PubMed, SciELO, and LILACS. The results demonstrated that the use of melanocortin-4 receptor agonists, such as setmelanotide, has shown efficacy in controlling appetite and reducing body weight. Additionally, drugs such as sertraline and risperidone are often indicated for the management of behavioral symptoms, such as anxiety and aggression, with promising results in improving quality of life. However, the incorporation of these therapies into the SUS is limited due to high costs and the lack of local studies validating their efficacy and safety in the Brazilian population. It is concluded that, despite therapeutic advances, there is a significant gap in the implementation of specific treatments for PWS in Brazil, highlighting the need for public policies that prioritize accessibility to innovative medicines and the promotion of national clinical studies.
References
Jensen D, et al. Somatostatin analogs in the management of Prader-Willi syndrome: A review of clinical outcomes and pharmacodynamics. J Endocrinol Metab. 2023. https://doi.org/10.1210/jendocr/met.2023-0294.
.
Liu J, et al. Multidisciplinary treatment strategies for Prader-Willi syndrome: A focus on behavioral interventions. J Child Psychol Psychiatry. 2023. https://doi.org/10.1111/jcpp.13687.
Matsumoto T, et al. Metabolic and cardiovascular risk factors in individuals with Prader-Willi syndrome: Implications for clinical management. Eur J Pediatr. 2023. https://doi.org/10.1007/s00431-023-04469-8.
Mikami T, et al. The role of GLP-1 agonists in the management of obesity and metabolic disorders in Prader-Willi syndrome. Clin Obes. 2024. https://doi.org/10.1111/cob.12483.
Rodrigues A, et al. Behavioral and psychological aspects of Prader-Willi syndrome: A focus on therapeutic strategies. J Clin Psychiatry. 2022. https://doi.org/10.4088/jcp.21r13789.
Rodrigues P, et al. Antipsychotic medications in the management of Prader-Willi syndrome: A comprehensive review of their effects and risks. Psychiatr Clin North Am. 2023. https://doi.org/10.1016/j.psc.2023.05.002.
Shapiro L, et al. Prader-Willi syndrome: Clinical characteristics, diagnosis, and treatment options. Int J Clin Med. 2023. https://doi.org/10.4236/ijcm.2023.121010.
Smith M, et al. Obesity and comorbidities in Prader-Willi syndrome: A critical review of the literature. J Pediatr Endocrinol Metab. 2022. https://doi.org/10.1515/jpem-2022-0078.
Vigoda T, et al. Psychopharmacological treatment in Prader-Willi syndrome: A review of medications for managing hyperphagia and behavioral issues. Psychiatry Res. 2024. https://doi.org/10.1016/j.psychres.2023.115872.
Zhang X, et al. Integrated approach for the treatment of Prader-Willi syndrome: The role of pharmacotherapy combined with behavioral and dietary interventions. Obes Rev. 2023. https://doi.org/10.1111/obr.13371.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 A.R International Health Beacon Journal (ISSN 2966-2168)